Loading...
Ripretinib: First Approval
Ripretinib (QINLOCK™) is a novel type II tyrosine switch control inhibitor being developed by Deciphera Pharmaceuticals for the treatment of KIT proto-oncogene receptor tyrosine kinase (KIT)-driven and/or platelet derived growth factor receptor A (PDGFRA)-driven cancers, including gastrointestinal s...
Saved in:
| Published in: | Drugs |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7595980/ https://ncbi.nlm.nih.gov/pubmed/32578014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01348-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|